This HTML5 document contains 214 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://dx.doi.org/10.1038/
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7https://scigraph.springernature.com/pub.10.1038/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q36648316
rdf:type
wikibase:Item
schema:description
vedecký článok 2003年論文 vetenskaplig artikel מאמר מדעי videnskabelig artikel наукова стаття, опублікована в серпні 2003 artículo científico publicado en 2003 2003年論文 article científic artículu científicu espublizáu en 2003 artigo científico আগস্ট ২০০৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ articolo scientifico 2003 nî lūn-bûn vědecký článek 2003年论文 scientific article published on August 2003 სამეცნიერო სტატია научни чланак научна статия 2003年论文 مقالة علمية نشرت في أغسطس 2003 επιστημονικό άρθρο scienca artikolo article scientific bài báo khoa học 2003年论文 scientific article published on August 2003 artikull shkencor 2003年論文 bilimsel makale vitskapeleg artikkel 2003年论文 articol științific научни чланак artigo científico artikel ilmiah 2003年论文 wetenschappelijk artikel vitenskapelig artikkel 2003年の論文 научная статья 2003년 논문 2003年論文 naučni članak article scientifique artykuł naukowy scientific article published on August 2003 artikulong pang-agham teaduslik artikkel 2003年论文 мақолаи илмӣ tieteellinen artikkeli บทความทางวิทยาศาสตร์ 2003年論文 tudományos cikk artigo científico wissenschaftlicher Artikel
p:P577
wds:Q36648316-8825C343-C45D-4B9D-9852-7BF88B1734D0
wdt:P577
2003-08-01T00:00:00Z
p:P407
wds:Q36648316-CC41F582-5359-4E9E-AAA2-D9E36AEB8E2D
wdt:P407
wd:Q1860
p:P2888
wds:Q36648316-8088B9C8-1213-4B3C-90DF-CEF051147ED9
wdt:P2888
n7:sj.bjc.6601147
p:P2860
wds:Q36648316-B51CAE26-5B3B-4BD5-85CE-CCC110708A7D wds:Q36648316-B660FC11-4E69-4ADE-9D8D-65313A0C230A wds:Q36648316-B8E8026D-FF37-436C-AE4F-A636B07B9A10 wds:Q36648316-BF2C11D0-4B3A-43DA-840D-24372CF019EF wds:Q36648316-C17D17A4-15AF-44BD-A6F6-D92DAF8F5EFF wds:Q36648316-C19DC47A-7B07-4B8E-BF9D-EE72AD920397 wds:Q36648316-C52C3BB4-AF77-4B99-A5F7-516E9225BF53 wds:Q36648316-C6FD81E2-73CE-4418-B458-A97E2594FF34 wds:Q36648316-C90BC2D2-8760-4DEA-8D4D-DB93AA6DD5F9 wds:Q36648316-633B3CAC-C5BD-4302-9A5C-610DB0B5D195 wds:Q36648316-6E0C26F5-7B2B-425C-9C8B-E8BD8A3DAE3F wds:Q36648316-6E764AB7-43E5-47CD-AFF4-D7E6FC462168 wds:Q36648316-7390E98F-22D8-49E2-AAC7-50E70838EE46 wds:Q36648316-7B5466D6-1F71-4BDE-91AF-431D776A3B61 wds:Q36648316-813645F6-8492-4028-84F9-2D6710303A1F wds:Q36648316-81D35599-039B-4A2B-9FD2-2CDEE2BB2BA0 wds:Q36648316-87E22D6E-65A3-4981-B6E8-CF2364FBE99B wds:Q36648316-8831F994-8390-4957-A4F4-C077001D0FBF wds:Q36648316-1A97A9A6-327A-439D-969D-C6A4B93C3629 wds:Q36648316-1D37BCEA-279A-4EC1-AE76-6F6EBB358CBE wds:Q36648316-282515DF-244D-47DF-91E8-E9B680A46009 wds:Q36648316-2945FBA4-D554-4779-9341-C8EDFC56A8E3 wds:Q36648316-2E5B97B9-A135-4568-9F9F-D18798AA393E wds:Q36648316-34B4C3A6-8FAB-4125-B194-070B1FD23605 wds:Q36648316-3C9FFFA5-5583-457B-84C5-F7D86E587125 wds:Q36648316-502AB136-20B9-427F-B993-965BB60AFF0E wds:Q36648316-548EA84D-755F-40B2-8489-9596B1CFA6BF wds:Q36648316-564F7243-BBB5-4EED-843D-29366492FF34 wds:Q36648316-5A38213A-C2EC-4131-91FF-DA597703F629 wds:Q36648316-5DA995EF-F244-4868-9A79-47CB3F63AE24 wds:Q36648316-6063FA1D-A4C0-43E4-97E8-A17EB0BE6504 wds:Q36648316-62DAAE5B-7974-47A7-A1A6-287A9158B866 wds:Q36648316-0B283483-CF92-4D72-BF95-EFFE363726D7 wds:Q36648316-11458E8C-7F23-447A-B78C-F9E63EB815FA wds:Q36648316-14F05979-39E3-446A-BC4B-82DD420A5338 wds:Q36648316-182B4395-24E2-4397-ADFD-5D95A013DAC1 wds:Q36648316-FD7DD38F-F673-418B-882F-B512513EBB6B wds:Q36648316-CD47D135-B362-4D5E-B5F1-FE74F1474F5B wds:Q36648316-D205D2A9-E050-45C9-9E3C-854A1277CE80 wds:Q36648316-D35503DE-378E-4C67-A64A-206EDB87E24D wds:Q36648316-DD26BA52-B573-42E9-B5B7-678DC385F60D wds:Q36648316-E2E63111-009D-49B6-A8C3-371E821C1638 wds:Q36648316-E98A4F5E-9304-4789-831F-49B3B34EAF26 wds:Q36648316-F7F840E3-B1E0-4EA8-8697-5B669E4842FB wds:Q36648316-FB0E006D-2031-4E4D-AB5C-3595B9962D99 wds:Q36648316-9851E1E7-6CDA-499C-AE1C-E086684558D1 wds:Q36648316-A1EAD906-F87C-455E-A6BB-52EFEF2F919B wds:Q36648316-A23B9FA1-AAEE-421B-8200-A5FBC5AA0C9F wds:Q36648316-A62DBCF7-77E3-46E2-884D-03D45A7CF37D
wdt:P2860
wd:Q53780736 wd:Q41639325 wd:Q41123551 wd:Q40627985 wd:Q68032784 wd:Q36431537 wd:Q74628245 wd:Q34448509 wd:Q33491452 wd:Q33498400 wd:Q72275131 wd:Q42213264 wd:Q73330191 wd:Q34511070 wd:Q53610419 wd:Q43629727 wd:Q33331282 wd:Q77669925 wd:Q71778659 wd:Q71079802 wd:Q33330638 wd:Q73492635 wd:Q36431552 wd:Q33487960 wd:Q71975354 wd:Q67486552 wd:Q39436075 wd:Q40800385 wd:Q41695542 wd:Q33503969 wd:Q33330597 wd:Q27748893 wd:Q31911584 wd:Q77323142 wd:Q40826947 wd:Q48017892 wd:Q33182306 wd:Q33795872 wd:Q34192665 wd:Q67671954 wd:Q32073589 wd:Q61868305 wd:Q74329771 wd:Q43478087 wd:Q44200284 wd:Q43850218 wd:Q73483006 wd:Q73566821 wd:Q43007521
p:P2093
wds:Q36648316-67F3B7E3-AEAB-44A7-8E7B-279154436259 wds:Q36648316-855B39EC-3C3F-4D54-89AC-378FE9C545C6 wds:Q36648316-9A226802-04A2-4F09-AD1B-973CBE82CAEF wds:Q36648316-E4A8C42A-1AFB-49AF-B92A-795027FEA6B3 wds:Q36648316-D36A3886-080C-468C-B4C6-ED19391FFD43 wds:Q36648316-F99A37C7-BC83-4D8C-BB81-F2F77D23607F wds:Q36648316-E4C46B42-1F06-4D3D-9FAF-961D804D650D wds:Q36648316-183B4D5B-C3BE-42E2-9052-602EB5AA044E
wdt:P2093
A J Davis A M Oza X Chen Q-L Yi M J Moore L L Siu D Kochman Z Kusenda
rdfs:label
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
skos:prefLabel
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
schema:name
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
p:P1476
wds:Q36648316-732ED7D4-77BB-42B9-B1A3-86EFF7275603
wdt:P1476
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
p:P304
wds:Q36648316-6B42C1CC-8964-48F6-A846-029018E2702B
wdt:P304
617-624
p:P31
wds:Q36648316-E5178E9A-4108-4C80-8F97-4C7EF4641A02
wdt:P31
wd:Q13442814
p:P921
wds:Q36648316-4867A3C6-3429-414C-BE03-A0828DDE5A0A
wdt:P921
wd:Q412197
p:P698
wds:Q36648316-F564AFC2-B298-4399-8DFF-33479F02B064
wdtn:P698
n12:12915867
wdt:P698
12915867
p:P1433
wds:Q36648316-8BD6BBCB-875D-4C04-B784-968882667F40
wdt:P1433
wd:Q326309
p:P433
wds:Q36648316-137A2D27-C832-4346-ABF5-AAAEA0EC8F9E
p:P478
wds:Q36648316-03117EFB-0A4E-46A8-81C0-AA0763E54B1A
wdt:P433
4
wdt:P478
89
p:P356
wds:Q36648316-CAC92B74-E590-4441-8A6B-DF90DB2AFB24
wdtn:P356
n11:SJ.BJC.6601147
wdt:P356
10.1038/SJ.BJC.6601147
p:P5875
wds:Q36648316-2FB7FCFB-DF52-449C-9B5F-BEAC709FC0D4
wdt:P5875
10615618
p:P6179
wds:Q36648316-DD76EBA0-3F80-475F-A71F-C8F65671C127
wdt:P6179
1017972055
p:P932
wds:Q36648316-E82DDD4A-3DF9-4EE6-B83A-06AD2B87516A
wdt:P932
2376925